Pembrolizumab,Pemetrexed,Cisplatin
Merck
[]
ind.227 presented today #asco2023 by dr chu. met all endpoints significantly improved survival with a 21% reduction in risk of death. 
The Investigational New Drug Program of the Canadian Cancer Trials Group